Bladder EpiCheck Product Development Study
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age22+
SponsorNucleix Ltd.
About this trial
This is a prospective, observational study to support the development of the Bladder EpiCheck kit by collecting urine samples from subjects suspected to have a bladder tumor or under NMIBC surveillance.
This is a single visit study. Each subject will sign the informed consent and provide voided urine sample. Demography and, if performed, pathology information will be collected for each subject.
Eligibility criteria
Qualifiers
Age 22 or older
Willing and able to sign the informed consent form
Disqualifiers
Patients with known or history of muscle invasive bladder cancer (MIBC)
Treatment of prostate cancer or RCC in the past 2 years
Patients previously enrolled into this study within the prior 60 days
Trial design
Treatments tested in this trial
- Bladder EpiCheck
Treatment groups
1,000 Participants
are divided into 3 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov